Adjuvant Pembrolizumab Reduces Recurrence Risk in High-Risk Resected Stage III Melanoma

Leggi l'articolo originale


Dr. Alexander Eggermont presented results of KEYNOTE-045/EORTC 1325-MG, in which melanoma patients with recurrence on placebo can receive pembrolizumab.

Lascia un commento